» Articles » PMID: 30051528

The Genetic Landscape of Anaplastic Pleomorphic Xanthoastrocytoma

Abstract

Pleomorphic xanthoastrocytoma (PXA) is an astrocytic neoplasm that is typically well circumscribed and can have a relatively favorable prognosis. Tumor progression to anaplastic PXA (WHO grade III), however, is associated with a more aggressive biologic behavior and worse prognosis. The factors that drive anaplastic progression are largely unknown. We performed comprehensive genomic profiling on a set of 23 PXAs from 19 patients, including 15 with anaplastic PXA. Four patients had tumor tissue from multiple recurrences, including two with anaplastic progression. We find that PXAs are genetically defined by the combination of CDKN2A biallelic inactivation and RAF alterations that were present in all 19 cases, most commonly as CDKN2A homozygous deletion and BRAF p.V600E mutation but also occasionally BRAF or RAF1 fusions or other rearrangements. The third most commonly altered gene in anaplastic PXA was TERT, with 47% (7/15) harboring TERT alterations, either gene amplification (n = 2) or promoter hotspot mutation (n = 5). In tumor pairs analyzed before and after anaplastic progression, two had increased copy number alterations and one had TERT promoter mutation at recurrence. Less commonly altered genes included TP53, BCOR, BCORL1, ARID1A, ATRX, PTEN, and BCL6. All PXA in this cohort were IDH and histone H3 wildtype, and did not contain alterations in EGFR. Genetic profiling performed on six regions from the same tumor identified intratumoral genomic heterogeneity, likely reflecting clonal evolution during tumor progression. Overall, anaplastic PXA is characterized by the combination of CDKN2A biallelic inactivation and oncogenic RAF kinase signaling as well as a relatively small number of additional genetic alterations, with the most common being TERT amplification or promoter mutation. These data define a distinct molecular profile for PXA and suggest additional genetic alterations, including TERT, may be associated with anaplastic progression.

Citing Articles

Diffusely Infiltrating Gliomas With Poor Prognosis, Promotor Mutations, and Histological Anaplastic Pleomorphic Xanthoastrocytoma-Like Appearance Classify as Mesenchymal Type of Glioblastoma, IDH-wildtype by Methylation Analysis.

Tsukamoto Y, Natsumeda M, Takahashi H, On J, Seto H, Saito T Neurosurg Pract. 2025; 4(2):e00040.

PMID: 39958377 PMC: 11810039. DOI: 10.1227/neuprac.0000000000000040.


Proton Beam Therapy for a Rare Anaplastic Pleomorphic Xanthoastrocytoma: Case Report and Literature Review.

Han W, Jin Y, Wang J, Zhang S, Hashimoto S, Wang Z Int J Part Ther. 2025; 15:100736.

PMID: 39885848 PMC: 11780143. DOI: 10.1016/j.ijpt.2024.100736.


Paediatric low-grade glioma: the role of classical pathology in integrated diagnostic practice.

Stone T, Merve A, Valerio F, Yasin S, Jacques T Childs Nerv Syst. 2024; 40(10):3189-3207.

PMID: 39294363 PMC: 11511714. DOI: 10.1007/s00381-024-06591-6.


Cortically Based Brain Tumors in Children: A Decision-Tree Approach in the Radiology Reading Room.

Rameh V, Lobel U, DArco F, Bhatia A, Mankad K, Poussaint T AJNR Am J Neuroradiol. 2024; 46(1):11-23.

PMID: 39181692 PMC: 11735440. DOI: 10.3174/ajnr.A8477.


Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging.

Yan J, Guo C, Zheng H, Li Y, Duan M, Zhang C BMC Cancer. 2024; 24(1):1022.

PMID: 39160463 PMC: 11331820. DOI: 10.1186/s12885-024-12713-9.


References
1.
Giannini C, Scheithauer B, Burger P, Brat D, Wollan P, Lach B . Pleomorphic xanthoastrocytoma: what do we really know about it?. Cancer. 1999; 85(9):2033-45. View

2.
Alves M, Faria M, Neves Filho E, Ferrasi A, de Moura Campos Pardini M, de Moraes Filho M . CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex. Int J Surg. 2013; 11(7):549-53. DOI: 10.1016/j.ijsu.2013.05.030. View

3.
Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones D . Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013; 126(6):907-15. DOI: 10.1007/s00401-013-1195-5. View

4.
Matsumura N, Nakajima N, Yamazaki T, Nagano T, Kagoshima K, Nobusawa S . Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma. Neuropathology. 2016; 37(1):58-63. DOI: 10.1111/neup.12318. View

5.
Vaubel R, Caron A, Yamada S, Decker P, Eckel Passow J, Rodriguez F . Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol. 2017; 28(2):172-182. PMC: 5807227. DOI: 10.1111/bpa.12495. View